Abstract:Dandan Wu, 1, &ast Junxiao Cong, 1, &ast Jiali Wei, 1 Jing Hu, 1 Wenhao Sun, 1 Wei Ran, 2 Chenghui Liao, 1 Housheng Zheng, 1 Liang Ye 1 1 Department of Immunology, International Cancer Center, Shenzhen University Health Science Center, Shenzhen, People's Republic of China; 2 State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Liang Ye, Department of Immunology, International Cancer Center, Shenzhen University Health Science Center, Shenzhen, 518055, People's Republic of China, Tel +86-0755-26631420, Fax +86-0755-86671943, Email Background: The emergence of the coronavirus disease 2019 (COVID-19) pandemic and the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOCs) requires the continuous development of safe, effective, and affordable prevention and therapeutics. Nanobodies have demonstrated antiviral activity against a variety of viruses, providing a new candidate for the prevention and treatment of SARS-CoV-2 and its variants. Methods: SARS-CoV-2 glycoprotein spike 1 subunit (S1) was selected as the target antigen for nanobody screening of a naïve phage display library. We obtained a nanobody, named Nb-H6, and then determined its affinity, inhibition, and stability by ELISA, Competitive ELISA, and Biolayer Interferometry (BLI). Infection assays of authentic and pseudotyped SARS-CoV-2 were performed to evaluate the neutralization of Nb-H6. The structure and mechanism of action were investigated by AlphaFold, docking, and residue mutation assays. Results: We isolated and characterized a nanobody, Nb-H6, which exhibits a broad affinity for S1 and the receptor binding domain (RBD) of SARS-CoV-2, or Alpha (B.1.1.7), Delta (B.1.617.2), Lambda (C.37), and Omicron (BA.2 and BA.5), and blocks receptor angiotensin-converting enzyme 2 (ACE2) binding. Moreover, Nb-H6 can retain its binding capability after pH or thermal treatment and effectively neutralize both pseudotyped and authentic SARS-CoV-2, as well as VOC Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (BA.2 and BA.5) pseudoviruses. We also confirmed that Nb-H6 binds two distinct amino acid residues of the RBD, preventing SARS-CoV-2 from interacting with the host receptor. Conclusion: Our study highlights a novel nanobody, Nb-H6, that may be useful therapeutically in SARS-CoV-2 and VOC outbreaks and pandemics. These findings also provide a molecular foundation for further studies into how nanobodies neutralize SARS-CoV-2 and variants and imply potential therapeutic targets for the treatment of COVID-19. Keywords: COVID-19, antiviral medication, single-domain antibody, neutralizing antibody, bio-screening The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) resulted in a global human health and economic crisis, having exceeded 763 million cases and 6.9 million deaths worldwide as of April 2023 ( https://www.who.int/ , accessed April 16, 2023). Despite the development of effective vaccines, eradicating SARS-CoV-2 remains extremely difficult due to waning immune responses from vaccination and the spread of new variants of concern (VOCs) such as Alpha, Beta, Gamma, and Delta, as well as the recently identified Omicron. 1–4 Given the ongoing SARS-CoV-2 pandemic and the possibility of new variants continuing to emerge, efforts to develop effective prophylactic and therapeutic strategies against emerging VOCs are urgently required. The SARS-CoV-2 glycoprotein spike (S) is a homotrimeric transmembrane protein that is responsible for viral entry into the host cell. 5–7 The S protein is composed of two functional subunits, S1 and S2, which are required for binding host cell angiotensin-converting enzyme 2 (ACE2) and catalyzing virus-cell membrane fusion. 5,7–9 The S1 subunit is further divided into a C-terminal receptor-binding domain (RBD) and an N-terminal domain (NTD), while the RBD directly binds to ACE2 to initiate cell recognition. 5,6 To date, RBD and NTD have been identified as targets of numerous neutralizing antibodies and inhibitors, 10–13 underlining that blocking S1 is crucial for the development of protective immunity against SARS-CoV-2 infection. The single-domain antibody (also known as nanobody, VHH, or Nb) derived from the heavy chain antibody of camelids has shown many advanta -Abstract Truncated-

A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

A Novel Nanobody Broadly Neutralizes SARS‐CoV‐2 Via Induction of Spike Trimer Dimers Conformation

A Potent Synthetic Nanobody with Broad-Spectrum Activity Neutralizes SARS-Cov-2 Virus and Omicron Variant Through a Unique Binding Mode

A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2

Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

A Potent Synthetic Nanobody with Broad-Spectrum Activity Neutralizes SARS-CoV-2 Virus and the Omicron Variant BA.1 Through a Unique Binding Mode

A potent neutralizing nanobody targeting a unique epitope on the receptor-binding domain of SARS-CoV-2 spike protein

A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern

A Non-Ace2 Competing Human Single-Domain Antibody Confers Broad Neutralization Against SARS-CoV-2 and Circulating Variants.

Nanobody engineering for SARS-CoV-2 neutralization and detection

Deep Generative Design of Neutralizing Nanobodies Against SARS-CoV-2 Variants

Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain

An Engineered Bispecific Nanobody in Tetrameric Secretory IgA Format Confers Broad Neutralization Against SARS-CoV-1&2 and Most Variants.

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants

Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1

Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization